Tag: Immunotherapeutics
OSE Immunotherapeutics: positive clinical results against ulcerative rectolitis – 02/22/2023 at 18:13
(AOF) – OSE Immunotherapeutics announces the publication in “The Journal of Immunology” of positive Phase 1 clinical results of OSE-127/S95011, an IL-7 receptor (IL-7R) antagonist, developed in partnership with Servier.…
OSE Immunotherapeutics has activated the second tranche of the EIB loan for 10 ME
(Boursier.com) — OSE Immunotherapeutics received a payment of 10 million euros under the 2nd tranche of the loan granted by the European Investment Bank in February 2021. After the drawdown…
OSE Immunotherapeutics receives a payment of 10 million euros for the 2nd tranche of the loan granted by the European Investment Bank – 2022/12/16 at 6:00 pm
This loan aims to support progress in clinical development programs for OSE Immunotherapeutics’ leading products in therapeutic areas with high medical need. Nantes, December 16, 2022, 6 p.m. – OSE…
OSE Immunotherapeutics presents the latest preclinical efficacy data of its IL-7 receptor antagonist OSE-127 in acute lymphoblastic leukemia at the 2022 ASH Annual Meeting – 12/12/2022 at 07:30
Nantes, France – December 12, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the latest preclinical data on the use of its IL-7 receptor antagonist (IL-7R)…
OSE Immunotherapeutics announces the publication in Science Advances of data on CLEC-1, its new myeloid immune checkpoint – 2022-11-21 at 18:00
Nantes, France – November 21, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the publication in the peer-reviewed journal Science Advances of data from a…
Unusual volumes on the stock market today: Ose Immunotherapeutics, McPhy Energy
During this trading session on Friday October 21, 2022, abnormal trading volumes were detected on the French market. Today, it is the Ose Immunotherapeutics share that stands out, with trading…
Ose Immunotherapeutics advances with Tedopi in lung cancer, the Stock Exchange applauds
Propelled on the stock market, the Nantes biotech has announced that it has received compassionate access authorizations in three European countries for its therapeutic vaccine candidate Tedopi against non-small cell…
OSE Immunotherapeutics provides an update on Tedopi®, a therapeutic cancer vaccine, a potential new reference treatment in non-small cell lung cancer after failure of immunotherapy – 10/20/2022 at 6:00 p.m.
Nantes, France – October 20, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), provides an update on Tedopi®, an immunotherapy for the activation of specific T lymphocytes…
OSE Immunotherapeutics presents advances in its Immuno-Oncology programs, BiCKI®-IL-7v and CLEC-1, at international conferences – 2022-10-12 at 18:00
Nantes, France – October 12, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces that three abstracts have been accepted for poster presentation at the 37th annual…
OSE Immunotherapeutics: Nicolas Poirier takes over as CEO
By Olivier Cheilan Published on 07/10/2022 at 6:13 p.m. (Boursier.com) —…
OSE Immunotherapeutics announces the appointment of Nicolas Poirier as Chief Executive Officer – 2022-10-07 18:00
Nantes, France – October 7, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), is pleased to announce the appointment of Dr. Nicolas Poirier as its new Chief…
Ose Immunotherapeutics: financial visibility until the third quarter of 2023 – 09/23/2022 at 10:48 am
(AOF) – Ose Immunotherapeutics reduced its losses in the first half of 2022. The net loss amounted to 1.979 million euros against a loss of 11.488 million in the first…